ASTRAZENECA RECEIVE HIGHLY COVETED FROST & SULLIVAN AWARD FOR ANASTROZOLE (ARIMIDEX(TM))

Frost & Sullivan has today awarded AstraZeneca the highly coveted 2005 Pharmaceutical Industry Product of the Year Award for its hormonal breast cancer therapy anastrozole ('Arimidex'). The Award recognises the advances in breast cancer treatment made by AstraZeneca through the development of anastrozole, a product now shown to be better at preventing the spread and return of cancer than tamoxifen -- previously considered to be the "gold standard" therapy.

Yahoo News (http://biz.yahoo.com/prnews/050920/ukf016.html?.v=4)